Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 4 , Pages 372-377 , July 2008

Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity

  • Joshua H. Petit, M.D.

      Affiliations

    • Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-617-667-2345; fax: +1-617-667-4990.
    • ,
  • Clifford Gluck, M.D.

      Affiliations

    • Department of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    • ,
  • W.S. Kiger III, Ph.D.

      Affiliations

    • Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    • ,
  • D. Laury Henry, B.S.

      Affiliations

    • Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    • ,
  • Carol Karasiewicz, B.S.

      Affiliations

    • Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    • ,
  • James Talcott, M.D.

      Affiliations

    • Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02214, USA
    • ,
  • Solomon Berg, M.D.

      Affiliations

    • Department of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    • ,
  • Edward Holupka, Ph.D.

      Affiliations

    • Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    • ,
  • Irving Kaplan, M.D.

      Affiliations

    • Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

Received 3 April 2007 ,Revised 28 April 2007 ,Accepted 8 May 2007.

References 

  1. Prestidge BR. Radioisotopic implantation for carcinoma of the prostate: Does it work better than it used to?. Semin Radiat Oncol. 1998;8:124–132
  2. Boccardo F, Pace M, Rubagotti A, et al. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer (The Italian Prostatic Cancer Project (PONCAP) Study Group). Eur J Cancer. 1993;29A:1088–1093
  3. Lamb DS, Denham JW, Mameghan H, et al. Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer. Radiother Oncol. 2003;68:255–267
  4. Metz R, Namer M, Adenis L, et al. Zoladex as primary therapy in advanced prostatic cancer (A French cooperative trial). Am J Clin Oncol. 1988;11(Suppl 2):112–S114
  5. Negat RJ, Rashid HH, Bagiella E, et al. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol. 2000;164:1891–1894
  6. Padula GD, Zelefsky MJ, Venkatraman ES, et al. Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;52:439–443
  7. Asbell SO, Leon SA, Tester WJ, et al. Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate. 1996;29:243–248
  8. Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass, and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. Urology. 2002;167:2361–2367
  9. Eri LM, Tveter KJ. Safety, side effects and patient acceptance of the luteinizing hormone releasing hormone agonist leuprolide in treatment of benign prostatic hyperplasia. J Urol. 1994;152:448–452
  10. Mittan D, Lee S, Miller E, et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endo Met. 2002;87:3656–3661
  11. Rosenblatt DE, Mellow A. Depression during hormonal treatment of prostate cancer. J Am Board Fam Pract. 1995;8:317–320
  12. Stone P, Hardy J, Huddart R, et al. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Canc. 2000;36:1134–1141
  13. Crook J, McLean M, Catton C, et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys. 2002;52:453–460
  14. Niehaus A, Merrick GS, Butler WM, et al. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;64:136–143
  15. Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol. 1998;160:1379–1382
  16. Vargas C, Ghilezan M, Hollander M, et al. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. J Urol. 2005;174:882–887
  17. Keating N, O'Malley J, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–4456
  18. Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: Results from two multicenter randomized trials at a median follow-up of four years. Urology. 1998;51:389–396
  19. Wirth M, Tyrrell C, Wallace M, et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology. 2001;58:146–150
  20. Eri LM, Tveter KJ. A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia. J Urol. 1993;150:90–94
  21. Eri LM, Tveter KJ. A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. J Urol. 1993;150:359–364
  22. Henderson A, Langley S, Laing RW. Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? (A prospective, observational study). Clin Oncol. 2003;15:318–321
  23. Clark JA, Rieker P, Propert KJ, et al. Changes in quality of life following treatment for early stage prostate cancer. Urology. 1999;53:161–168
  24. Clark JA, Talcott J. Symptom indexes to assess outcomes of treatment for early stage prostate cancer. Medical Care. 2001;39:1118–1130
  25. Kucway R, Vicini F, Huang R, et al. Prostate volume reduction with androgen deprivation before interstitial brachytherapy. J Urol. 2002;167:2443–2447
  26. Whittington R, Broderick G, Arger P, et al. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1999;44:1107–1111
  27. Narayan P, Trachtenberg J, Lepor H, et al. A dose-response study of the effect of flutamide on benign prostatic hyperplasia: Results of a multicenter study. Urology. 1996;47:497–504
  28. Boccardo F, Rubagotti A, Barichello M, et al. Bicalutamide monotherapy vs. flutamide plus goserelin in prostate cancer patients: Results of an Italian Prostate Cancer Project study. J Clin Oncol. 1999;17:2027–2038
  29. Tyrrell CJ, Blake GM, Iversen P, et al. The nonsteroidal antiandrogen, bicalutamide (Casodex), may preserve bone mineral density compared with castration: Results of a preliminary study. World J Urol. 2003;21:37–42

PII: S1078-1439(07)00138-X

doi: 10.1016/j.urolonc.2007.05.014

Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 4 , Pages 372-377 , July 2008

Article Tools

* Image Usage & Resolution